LeserbriefKommentar
Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis
JAMA · 2023
DOI: 10.1001/jama.2022.22646 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Brandon Smith und 2 weiteren Autor:innen. Beteiligte Einrichtung: Drexel University College of Medicine, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Psoriasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Phosphodiesterase 4 InhibitorsPsoriasisHumansAminopyridinesBenzamidesChronic DiseaseCyclopropanesDouble-Blind MethodSeverity of Illness IndexSkin CreamTreatment OutcomeAdministration, Cutaneous
Substanzen
AminopyridinesBenzamidesCyclopropanesPhosphodiesterase 4 InhibitorsRoflumilast
Autor:innen und Institutionen
- Drexel University College of Medicine, Philadelphia, Pennsylvania.
- USF Health Morsani College of Medicine, Tampa, Florida.
- University of Miami Miller School of Medicine, Miami, Florida.
Zitieren
APA
Smith, B., Collier, M. R., & Wu, J. J. (2023). Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis. JAMA. https://doi.org/10.1001/jama.2022.22646
Vancouver
Smith B, Collier MR, Wu JJ. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis. JAMA. 2023. doi:10.1001/jama.2022.22646
BibTeX
@article{Smith2023,
author = {Smith, Brandon and Collier, Michael R and Wu, Jashin J},
title = {Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2022.22646}
}
EUVIMED